Cirrhosis Statin Trial Yields Mixed Efficacy Data

A Phase III study on simvastatin for compensated cirrhosis patients found a near-miss in statistical significance for preventing hepatic decompensation and liver cancer. However, the trial did show a significant 51-day survival advantage with statin therapy and indicated safety for cirrhosis patients. Further research is needed to confirm statins' role in reducing these events.